Among central nervous system tumors, Glioblastoma (GBM) is the most common, aggressive
and neurological destructive primary brain tumor in adults. Standard care therapy for GBM …

Gene therapy has the potential to provide therapeutic benefit to millions of people with
neurodegenerative diseases through several means, including direct correction of …

Glioblastoma (GBM) is a particularly aggressive brain cancer associated with high
recurrence and poor prognosis. The standard of care, surgical resection followed by …

Glioblastoma is the most common malignant brain tumor, and it carries an extremely poor
prognosis. Attempts to develop targeted therapies have been hindered because the blood …

Effective treatment of glioblastoma (GBM) remains a formidable challenge. Survival rates
remain poor despite decades of clinical trials of conventional and novel, biologically …

Convection-enhanced delivery (CED) is a method used to increase transport of therapeutics
in and around brain tumors. CED works through locally applying a pressure differential to …

The etiology of many neurological diseases affecting the central nervous system (CNS) is
unknown and still needs more effective and specific therapeutic approaches. Gene therapy …

The brain is highly accessible for nutrients and oxygen, however delivery of drugs to
malignant brain tumors is a very challenging task. Convection-enhanced delivery (CED) has …

Despite recent advances in tumor imaging and chemoradiotherapy, the median overall
survival of patients diagnosed with glioblastoma multiforme does not exceed 15 months …

Malignant gliomas are the most frequently occurring, devastating primary brain tumors, and
are coupled with a poor survival rate. Despite the fact that complete neurosurgical resection …